文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

同种异体嵌合抗原受体T细胞疗法的进展：平台、当前进展及局限性

Allogeneic CART progress: platforms, current progress and limitations.

作者信息

Shokati Ameneh, Sanjari-Pour Maryam, Akhavan Rahnama Mahshid, Hoseinzadeh Saghar, Vaezi Mohammad, Ahmadvand Mohammad

机构信息

Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Department of Clinical Biochemistry, Faculty of Medical Science, Tarbiat Modarres University, Tehran, Iran.

出版信息

Front Immunol. 2025 Jun 12;16:1557157. doi: 10.3389/fimmu.2025.1557157. eCollection 2025.

DOI:10.3389/fimmu.2025.1557157
PMID:40574859
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12198129/
Abstract

Allogenic chimeric antigen receptor T (CAR-T) cells have advantages compared to autologous T cell therapies such as availability cells for production, a suitable HLA-matched donor (if graft-vs-host-disease and rejection effects are to be avoided and also lower risks associated with transduction methods in process of autologous CAR-T cells). In recent years, the additional editing and non-editing technologies are helping to make allogenic CAR-T therapies a hopeful future treatment. Universal off-the-shelf CAR-T cells can be solved key issues include preventing graft-versus-host disease (GVHD) and time consumption and other challenges faced to allogenic CAR-T cells. Here, we have highlighted the improvement in CAR-T development, particularly in engineering allogenic CAR-T, clinical practices related to these, pre-clinical and clinical studies and their successes which investigated in recent 10 years related to treatment of hematological malignancies and cancers by allogenic CAR-T cells.

摘要

与自体T细胞疗法相比，同种异体嵌合抗原受体T（CAR-T）细胞具有诸多优势，例如生产可用的细胞、合适的HLA匹配供体（若要避免移植物抗宿主病和排斥反应，以及与自体CAR-T细胞过程中的转导方法相关的较低风险）。近年来，额外的编辑和非编辑技术有助于使同种异体CAR-T疗法成为充满希望的未来治疗方法。通用的现成CAR-T细胞可以解决关键问题，包括预防移植物抗宿主病（GVHD）以及同种异体CAR-T细胞面临的时间消耗和其他挑战。在此，我们重点介绍了CAR-T开发方面的进展，特别是在工程化同种异体CAR-T方面、与之相关的临床实践、临床前和临床研究，以及近10年来在同种异体CAR-T细胞治疗血液系统恶性肿瘤和癌症方面的研究成果及其成功案例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e98/12198129/74705afaa917/fimmu-16-1557157-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e98/12198129/aed8f0a25a1b/fimmu-16-1557157-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e98/12198129/2f7816c38dca/fimmu-16-1557157-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e98/12198129/964a8eb88c82/fimmu-16-1557157-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e98/12198129/74705afaa917/fimmu-16-1557157-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e98/12198129/aed8f0a25a1b/fimmu-16-1557157-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e98/12198129/2f7816c38dca/fimmu-16-1557157-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e98/12198129/964a8eb88c82/fimmu-16-1557157-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e98/12198129/74705afaa917/fimmu-16-1557157-g004.jpg

相似文献

[1]
Allogeneic CART progress: platforms, current progress and limitations.

Front Immunol. 2025-6-12

[2]
Managing allorejection in off-the-shelf CAR-engineered cell therapies.

Mol Ther. 2024-11-26

[3]
Clinical development of allogeneic chimeric antigen receptor αβ-T cells.

Mol Ther. 2025-6-4

[4]
CAR-NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor.

Immun Inflamm Dis. 2025-6

[5]
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.

N Engl J Med. 2024-4-25

[6]
Transduction of γδ T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications.

Front Immunol. 2025-6-6

[7]
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.

Mol Ther. 2019-4-8

[8]
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.

Cochrane Database Syst Rev. 2021-9-13

[9]
Off the shelf T cell therapies for hematologic malignancies.

Best Pract Res Clin Haematol. 2018-6

[10]
Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.

Immunotherapy. 2017-1

引用本文的文献

[1]
Unconventional Immunotherapies in Cancer: Opportunities and Challenges.

Pharmaceuticals (Basel). 2025-8-4

本文引用的文献

[1]
iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment.

Bioengineering (Basel). 2025-1-13

[2]
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.

Front Cell Dev Biol. 2024-11-18

[3]
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.

Lancet Oncol. 2025-1

[4]
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.

Nat Rev Clin Oncol. 2025-1

[5]
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.

JAMA. 2024-12-10

[6]
Overview of approved CAR-T products and utility in clinical practice.

Clin Hematol Int. 2024-10-23

[7]
Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances.

Best Pract Res Clin Haematol. 2024-9

[8]
Current Strategies to Improve Chimeric Antigen Receptor T (CAR-T) Cell Persistence.

Cureus. 2024-7-24

[9]
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.

Intensive Care Med. 2024-9

[10]
Approved CAR-T therapies have reproducible efficacy and safety in clinical practice.

Hum Vaccin Immunother. 2024-12-31

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索